Although recent advancements CKD treatment, such as the introduction of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 agonists, have shown improvements, some patients still experience a persistent decline in renal function. This evidence concerns the gene SLC5A2 and chronic kidney disease.